{
    "nct_id": "NCT06542250",
    "official_title": "A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)",
    "inclusion_criteria": "* ≥18 years of age;\n* Histologically documented CD20+ mature B-cell neoplasm\n\n  * Large B-cell lymphoma\n  * Follicular lymphoma\n  * Mantle cell lymphoma\n  * Chronic lymphocytic leukemia\n  * Small lymphocytic lymphoma\n* Relapsed, progressive and/or refractory disease following at least 2 prior lines of therapy;\n* ECOG performance status of ≤ 2 (< 2 in EU countries).\n\nThe above is a summary, other inclusion criteria details may apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any neoplasm histology not specified in the IC section;\n* Active CNS involvement in lymphoma;\n* CNS pathology including but not limited to any history of seizure disorder/epilepsy;\n* Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy;\n* History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS;\n* Active and uncontrolled infections;\n* Unresolved AEs ≥2 Grade due to prior anticancer therapies, with some exceptions\n\nThe above is a summary, other exclusion criteria details may apply.",
    "miscellaneous_criteria": ""
}